On the stock market since 2007, it operates in the world of health and science. It has 44,000 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
An average decline of 9% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.13 per share each year — regular cash for whoever holds the stock.
A loss of $59.0M against $3.9B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, GENN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GENN has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.